Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

203391 (-)-Blebbistatin - CAS 856925-71-8 - Calbiochem

203391
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Empirical FormulaCAS #
C₁₈H₁₆N₂O₂856925-71-8

Products

Catalogue NumberPackaging Qty/Pack
203391-1MG Plastic ampoule 1 mg
Description
OverviewThe active enantiomer of (±)-Blebbistatin (Cat. No. 203390) that accounts for the inhibitory activity towards ATPase (IC50 = ~2 µM) and myosin II-dependent cellular processes. Also reported to potently inhibit the actomyosin ATPase activities of expressed smooth muscle myosin IIA (SMA) and smooth muscle myosin IIB (SMB) smooth muscle myosin II heavy-chain isoforms (IC50 ~3 µM).
Catalogue Number203391
Brand Family Calbiochem®
References
ReferencesEddinger, T.J. et al. 2007. J. Pharmacol. Exp. Ther. 320, 865.
Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA 102, 1472.
Kovacs, M., et al. 2004. J. Biol. Chem. 279, 35557.
Straight, A.F., et al. 2003. Science 299, 1743.
Product Information
CAS number856925-71-8
ATP CompetitiveN
FormYellow solid
Hill FormulaC₁₈H₁₆N₂O₂
Chemical formulaC₁₈H₁₆N₂O₂
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetATPase
Primary Target IC<sub>50</sub>2 µM
Purity≥98% by Chiral HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Harmful & Carcinogenic / Teratogenic
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month in 90% DMSO or methanol (-20°C). Stock solutions in 100% DMSO are unstable; reconstitute just prior to use.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

(-)-Blebbistatin - CAS 856925-71-8 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

(-)-Blebbistatin - CAS 856925-71-8 - Calbiochem Certificates of Analysis

TitleLot Number
203391

References

Reference overview
Eddinger, T.J. et al. 2007. J. Pharmacol. Exp. Ther. 320, 865.
Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA 102, 1472.
Kovacs, M., et al. 2004. J. Biol. Chem. 279, 35557.
Straight, A.F., et al. 2003. Science 299, 1743.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision31-March-2011 RFH
DescriptionThe active enantiomer of (±)-Blebbistatin (Cat. No. 203390) that accounts for the inhibitory activity toward ATPase (IC50 ~2 µM) and myosin II-dependent cellular processes. Also reported to potently inhibit the actomyosin ATPase activities of expressed smooth muscle myosin IIA (SMA) and smooth muscle myosin IIB (SMB) smooth muscle myosin II heavy-chain isoforms (IC50 ~3 µM).
FormYellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number856925-71-8
Chemical formulaC₁₈H₁₆N₂O₂
Structure formulaStructure formula
Purity≥98% by Chiral HPLC
Solubility100% DMSO (100 mg/ml), 90% DMSO (75 mg/ml) or Methanol (1.5 mg/ml)
Storage -20°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month in 90% DMSO or methanol (-20°C). Stock solutions in 100% DMSO are unstable; reconstitute just prior to use.
Toxicity Harmful & Carcinogenic / Teratogenic
ReferencesEddinger, T.J. et al. 2007. J. Pharmacol. Exp. Ther. 320, 865.
Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA 102, 1472.
Kovacs, M., et al. 2004. J. Biol. Chem. 279, 35557.
Straight, A.F., et al. 2003. Science 299, 1743.